Candel Therapeutics (CADL) Accumulated Depreciation & Amortization (2020 - 2025)
Candel Therapeutics recorded quarterly Accumulated Depreciation & Amortization of $3.6 million in Q4 2025, up 3.82% quarter-over-quarter from $3.4 million in Q3 2025, and up 15.67% year-over-year from $3.1 million in Q4 2024.
Candel Therapeutics' Accumulated Depreciation & Amortization history runs 6 years deep, the most recent figure standing at $3.6 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation & Amortization rose 15.67% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (up 15.67% YoY), while the FY2025 annual figure was $3.6 million, up 15.67% from the prior year.
- Accumulated Depreciation & Amortization came in at $3.6 million for Q4 2025 at Candel Therapeutics, up from $3.4 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.6 million in Q2 2025 to a low of $22000.0 in Q3 2021.
- A 5-year average of $1.6 million and a median of $1.3 million in 2022 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization plunged 74.12% in 2021 and soared 2627.27% in 2022, its largest moves.
- Candel Therapeutics' Accumulated Depreciation & Amortization stood at $200000.0 in 2021, then soared by 300.0% to $800000.0 in 2022, then jumped by 161.12% to $2.1 million in 2023, then jumped by 47.25% to $3.1 million in 2024, then gained by 15.67% to $3.6 million in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $3.6 million, $3.4 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.56 Mn |
| Dec 31, 2025 | 3.56 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 800,000.00 |
| Dec 31, 2022 | 800,000.00 |
| Sep 30, 2022 | 600,000.00 |
| Sep 30, 2022 | 600,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Dec 31, 2021 | 200,000.00 |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Dec 31, 2020 | 91,000.00 |
| Dec 31, 2020 | 91,000.00 |
| Sep 30, 2020 | 85,000.00 |
| Sep 30, 2020 | 85,000.00 |
| Jun 30, 2020 | 40,000.00 |
| Jun 30, 2020 | 40,000.00 |